Aurobindo Pharma's Dyrupeg Biosimilar Receives Health Canada Approval for Cancer Neutropenia Treatment
Key Insights
CuraTeQ Biologics (search), a subsidiary of Aurobindo Pharma, has received Notice of Compliance from Health Canada for Dyrupeg, a pegylated filgrastim biosimilar indicated for cancer (search) patients with low neutrophil counts.
Health Canada's approval confirms Dyrupeg demonstrates high similarity to an approved reference biologic drug with no clinically meaningful differences in safety or quality attributes.
The Canadian approval follows Dyrupeg's marketing authorization in the European Union and UK in 2025, expanding the biosimilar's global regulatory footprint.
CuraTeQ Biologics (search) Pvt Ltd, a subsidiary of Aurobindo Pharma Ltd, has secured a Notice of Compliance (NOC) from Health Canada for its biosimilar drug Dyrupeg, marking a significant regulatory milestone for the pegylated filgrastim biosimilar indicated for cancer (search) patients with low neutrophil levels.
Regulatory Approval Details
The NOC was granted by Health Canada's Biologics and Radiopharmaceutical Drugs Directorate (BRDD) following a successful regulatory review. According to Aurobindo Pharma's regulatory filing, the approval confirms that Dyrupeg meets stringent regulatory standards for safety, efficacy, and quality under the food and drug regulations.
Health Canada's approval specifically indicates that the regulatory body has verified Dyrupeg's high similarity to an approved reference biologic drug, with no clinically meaningful differences in terms of safety or other quality attributes. This determination is crucial for biosimilar approval, as it demonstrates therapeutic equivalence to the reference product.
Clinical Indication and Patient Population
Dyrupeg is indicated for cancer (search) patients experiencing low levels of neutrophils (search), a type of white blood cell that serves as a critical component of the immune system. Neutropenia (search) is a common and serious side effect of cancer chemotherapy that can increase patients' risk of infection and may require treatment delays or dose reductions.
Global Market Expansion
The Canadian approval represents an expansion of Dyrupeg's regulatory footprint beyond its initial approvals. In 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC) and from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.
This series of regulatory approvals positions CuraTeQ Biologics (search) to compete in multiple major pharmaceutical markets with its pegylated filgrastim biosimilar, potentially offering healthcare systems and patients a more cost-effective alternative to reference biologic treatments for chemotherapy-induced neutropenia (search).